HIV protease inhibitors block adipogenesis and increase lipolysis in vitro

Antiviral Research

Volumn 47, Issue 2, 2000, Pages 121-129

  Lenhard, James M ^a   Furfine, Eric S ^a   Jain, Renu G ^a   Ittoop, Olivia ^a   Orband Miller, Lisa A ^a   Blanchard, Steven G ^a   Paulik, Mark A ^a   Weiel, James E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adipogenesis; HIV; Lipodystrophy; Lipolysis; Protease inhibitors

Indexed keywords

4 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)ETHENYL]BENZOIC ACID; AMPRENAVIR; FAT DROPLET; FATTY ACID BINDING PROTEIN; INDINAVIR; LIPOPROTEIN LIPASE; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; RECEPTOR SUBTYPE; RETINOID X RECEPTOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; IC 50; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; METABOLIC INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

ADIPOCYTES; ANIMAL; AZO COMPOUNDS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; DYES; HIV PROTEASE INHIBITORS; INDINAVIR; INSULIN; LIPOLYSIS; LIPOPROTEIN LIPASE; NELFINAVIR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RITONAVIR; RNA, MESSENGER; SAQUINAVIR; STEM CELLS; SULFONAMIDES; TETRAHYDRONAPHTHALENES; THIAZOLES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0033829565     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00102-9     Document Type: Article

References (50)

1. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee V.K., O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:1997;3149-3153.
2. Balani S.K., Woolf E.J., Hoagland V.L., Sturgill M.G., Deutsch P.J., Yeh K.C., Lin J.H. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Disposition. 24:1996;1389-1394.
3. Baldo A., Sniderman A.D., St-Luce S., Avramoglu R.K., Maslowska M., Hoang B., Monge J.C., Bell A., Mulay S., Cianflone K. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J. Clin. Invest. 92:1993;1543-1547.
4. Boehm M.F., Zhang L., Badea B.A., White S.K., Mais D.E., Berger E., Suto C.M., Goldman M.E., Heyman R.A. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 37:1994;2930-2941.
5. Brinkman K., ter Hofstede H.J., Burger D.M., Smeitink J.A., Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial]. AIDS. 12:1998;1735-1744.
6. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of anti retroviral-therapy-related lipodystrophy. Lancet. 354:1999;111-115.
7. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
8. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
9. Flexner C. HIV-protease inhibitors. New Engl. J. Med. 338:1998;1281-1292.
10. Gagnon A., Angel J.B., Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture [letter]. Lancet. 352:1998;1032.
11. Galli M., Ridolfo A.L., Gervasoni C., Ravasio L., Adorni F., Moroni M. Incidence of fat tissue wasting abnormalities in protease inhibitor-naive patients treated with NRTI combinations. Antiviral Res. 4(suppl. 2):1999;29.
12. Geloen A., Roy P.E., Bukowiecki L.J. Regression of white adipose tissue in diabetic rats. Am. J. Physiol. 257:1989;E547-E553.
13. Havlir D.V., Lange J.M. New antiretrovirals and new combinations [published erratum appears in AIDS 1998 Oct 22;12(15):following 2087]. AIDS. 12:1998;S165-S174.
14. Hsu A., Granneman G.R., Witt G., Locke C., Denissen J., Molla A., Valdes J., Smith J., Erdman K., Lyons N., Niu P., Decourt J.P., Fourtillan J.B., Girault J., Leonard J.M. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:1997;898-905.
15. Ipp M.M., Minta J.O., Gelfand E.W. Disorders of the complement system in lipodystrophy. Clin. Immunol. Immunopathol. 7:1977;281-287.
16. Jarvis B., Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 56:1998;147-167.
17. Kaul D.R., Cinti S.K., Carver P.L., Kazanjian P.H. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy. 19:1999;281-298.
18. Kenakin, T., Lenhard, J.M., Paulik, M.A., 1998. β-Adrenoreceptor assays. In: Enna, S.J., Williams, M. (Eds.), Current Protocols in Pharmacology. Wiley, New York pp. 4.6.1-4.6.36.
19. Kletzien R.F., Clarke S.D., Ulrich R.G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41:1992;393-398.
20. Krotkiewski M., Bjorntorp P. The effect of progesterone and of insulin administration on regional adipose tissue cellularity in the rat. Acta Physiol. Scand. 96:1976;122-127.
21. Lea A.P., Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs. 51:1996;846-864.
22. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:1995;12953-12956.
23. Lenhard J.M., Kliewer S.A., Paulik M.A., Plunket K.D., Lehmann J.M., Weiel J.E. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem. Pharmacol. 54:1997;801-808.
24. Lenhard, J.M., Furfine, E., Croom, D., Spaltenstein, A., Weiel, J., 1999a. Effect of HIV-protease inhibitors on in vitro adipogenesis and in vivo fat deposition. Antiviral Res. 4 (Suppl. 2), 3.
25. Lenhard J.M., Lancaster M.E., Paulik M.A., Weiel J.E., Binz J.G., Sundseth S.S., Gaskill B.A., Lightfoot R.M., Brown H.R. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia. 42:1999;545-554.
26. Lenhard J.M., Weiel J.E., Paulik M.A., Furfine E.S. Stimulation of vitamin A signaling by the HIV protease inhibitor indinavir. Biochem. Pharmacol. 59:2000;1063-1068.
27. Levy Y., George J., Yona E., Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunologic Res. 18:1998;55-60.
28. Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1:1995;417-422.
29. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M. 'Buffalo hump' in men with HIV-1 infection [see comments]. Lancet. 351:1998;867-870.
30. Mallal S., John M., Moore C., James I., McKinnon E. Protease inhibitors and nucleoside analog reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection. Antiviral Res. 4(suppl. 2):1999;28.
31. Martin R.J., Hausman G.J., Hausman D.B. Regulation of adipose cell development in utero. Proc. Soc. Exp. Biol. Med. 219:1998;200-210.
32. Miller K.D., Jones E., Yanovski J.A., Shankar R., Feuerstein I., Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir [see comments]. Lancet. 351:1998;871-875.
33. Mukherjee R., Davies P.J., Crombie D.L., Bischoff E.D., Cesario R.M., Jow L., Hamann L.G., Boehm M.F., Mondon C.E., Nadzan A.M., Paterniti J.R. Jr, Heyman R.A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 386:1997;407-410.
34. Nichols J.S., Parks D.J., Consler T.G., Blanchard S.G. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal. Biochem. 257:1998;112-119.
35. Novikoff A.B., Novikoff P.M., Rosen O.M., Rubin C.S. Organelle relationships in cultured 3T3-L1 preadipocytes. J. Cell Biol. 87:1980;180-196.
36. Pai V.B., Nahata M.C. Nelfinavir mesylate: a protease inhibitor. Ann. Pharmacother. 33:1999;325-339.
37. Palella F.J. Jr, Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. New Engl. J. Med. 338:1998;853-860.
38. Paulik M.A., Lenhard J.M. Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tiss. Res. 290:1997;79-87.
39. Peake P.W., O'Grady S., Pussell B.A., Charlesworth J.A. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur. J Clin. Invest. 27:1997;922-927.
40. Rose M.L., Paulik M.A., Lenhard J.M. Therapeutic approaches to Type 2 diabetes mellitus. Exp. Opin. Ther. Patents. 9:1999;1223-1236.
41. Rosen O.M., Smith C.J., Hirsch A., Lai E., Rubin C.S. Recent studies of the 3T3-L1 adipocyte-like cell line. Recent Prog. Hor. Res. 35:1979;477-499.
42. Saint-Marc T., Partisani M., Poizot-Martin I., Bruno F., Rouviere O., Lang J.-M., Gastrut J.-A., Touraine J.-L. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 13:1999;1659-1667.
43. Schooley R.T. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin. Infect. Dis. 29:1999;12-18.
44. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
45. Shimomura I., Hammer R.E., Richardson J.A., Ikemoto S., Bashmakov Y., Goldstein J.L., Brown M.S. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 12:1998;3182-3194.
46. Sissons J.G., West R.J., Fallows J., Williams D.G., Boucher B.J., Amos N., Peters D.K. The complement abnormalities of lipodystrophy. New Engl. J. Med. 294:1976;461-465.
47. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
48. Walli R., Herfort O., Michl G.M., Demant T., Jager H., Dieterle C., Bogner J.R., Landgraf R., Goebel F.D. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 12:1998;F167-F173.
49. Wenworth J.M., Burris T.P., Chatterjee V.K.K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR gamma/RXR heterodimer. J. Endocrinol. 164:2000;R7-R10.
50. Zhang B., Macnaul K., Szalkowski D., Li Z., Berger J., Moller D.E. Inhibition of adipocyte differentiation by HIV protease inhibitors. Clin. Endocrin. Metab. 84:1999;4274-4277.